ValiRx Share News (VAL)

ValiRx Losses Widen But Says Compounds Progressing In Trials

ValiRx granted patent in Australia for VAL201 targeting cancer

ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia. The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormon

ValiRx to present at key Cancer Conference

Shares in life science company ValiRx rose on Tuesday morning after the AIM-listed company announced that it would be presenting at the American Association for Cancer Research Conference this year. The conference, which was attended by approximately 17,000 delegates last year, is seen as a key eve

ValiRx appoints COO to help build portfolio

Biotech firm ValiRx has appointed a Chief Operating Officer to assist in building and adding value to its portfolio of technologies and to coordinate ValiRx's commercial strategy. Samual Ogunsalu has a background in Microbiology and Biochemical engineering and has 15 years' experience in the identi

Small cap round-up: InterQuest, ValiRx, Aeorema Comms

InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m p

Contract wins round-up: LO-Q, Motive TV, Plexus ...

Lo-Q has announced its second contract win of the week, as an unnamed major US theme park operator has signed up to use the firm's virtual queueing system at two sites in the US. Revenue associated with the agreement is expected to scale gradually, over time. In addition, the deal grants that Lo-Q's

Small cap round-up: ValiRx, Transense, Sweett

Shares in ValiRx, the life sciences firm, leapt almost 40% on Tuesday after it said independent trials had confirmed the effectiveness of its prostate cancer drug VAL201. The firm said the "significant and substantively important findings" showed its drug reduced the spread of secondary tumours by u

Small caps round-up: Cello, DDD, Kewill...

Marketing firm Cello Group has reported good trading during the first three months of the year, reflecting 'the strong pipeline of work secured at the end of 2011 and a solid flow of bookings'. The research and consulting division was a strong performer, while the group's focus on the pharmaceutic

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Small caps round-up: Rock Solid, ValiRx, InternetQ, Quindell

Rock Solid Images, an oil equipment, services and distribution firm, has received an offer from Thalassa Holdings to acquire up to 25.89 per cent of the company for 0.48p per share in cash. Rock Solid is concerned that Thalassa has provided no evidence that they will bring any "added economic or ind

Small caps round-up: Caza, Tower Resources, Noventa...

Mining firm Noventa says that operations have suffered from a "plague" of beetles as a result of tropical storms which have hit the firm's Marropino site in Mozambique over the past 10 days. The Rove Beetle is very poisonous and around 30% of the workforce at Marropino have been affected by the seve

Valirx wins Canadian patent for 'gene-silencing' technology

ValiRx, the AIM listed life sciences firm, saw its share price surge on news that its 'gene-silencing' technology has received patent approval in Canada. It already has patents for the US, Europe and Australia. ValiRx is developing treatments which "silence" so called rebellious genes that can cau

ValiRx Begins Clinical Validation Of HPV Test

LONDON (Dow Jones)--ValiRx PLC (VAL.LN), a life science company with a focus on cancer diagnostics and therapeutics for personalized medicine, said Thursday its human papilloma virus, or HPV, smear test to detect the onset of cervical cancer in women has now begun clinical sample validation. MAI

Small caps round-up: Nyota Minerals, Mariana Resources, Bluestar...

Miner Nyota Minerals said drilling at its flagship Tulu Kapi gold project in Ethiopia has confirmed the presence of a new mineralized structure beneath the inferred resource of 1.38m ounces of gold. Also in gold mining, Mariana Resources said it made an encouraging intersection of gold north of the

ValiRx Completes 1st Yr Eurostars Program, All Milestones Met

LONDON (Dow Jones)--ValiRx Plc (VAL.LN), a life science company with a focus on cancer diagnostics and therapeutics for personalized medicine, announced Thursday that it has completed the first year of a two year Eurostars grant program (total budget EUR1.2 million) in which all developmental milest